key: cord-0977248-gzrzxs9v
authors: de León, Ugo Avila-Ponce; Avila-Vales, Eric; Huang, Kuan-lin
title: Modeling COVID-19 dynamic using a two-strain model with vaccination
date: 2022-02-16
journal: Chaos Solitons Fractals
DOI: 10.1016/j.chaos.2022.111927
sha: 7657a9eb8c746ab058b7fdcb4a990fe95f473594
doc_id: 977248
cord_uid: gzrzxs9v

Multiple strains of the SARS-CoV-2 have arisen and jointly influence the trajectory of the coronavirus disease (COVID-19) pandemic. However, current models rarely account for this multi-strain dynamics and their different transmission rate and response to vaccines. We propose a new mathematical model that accounts for two virus variants and the deployment of a vaccination program. To demonstrate utility, we applied the model to determine the control reproduction number [Formula: see text] and the per day infection, death and recovery rates of each strain in the US pandemic. The model dynamics predicted the rise of the alpha variant and shed light on potential impact of the delta variant in 2021. We obtained the minimum percentage of fully vaccinated individuals to reduce the spread of the variants in combination with other intervention strategies to deaccelerate the rise of a multi-strain pandemic.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in 2019 and has since amounted to over 388 million confirmed cases and 5.7 million confirmed deaths around the globe [1] . Much of the world struggled throughout 2020 to slow the spread of the virus by implementing nonpharmaceutical strategies (NPI's), such as partial or total lockdowns, the usage of face masks, among others [2] , although these measures were sometimes insufficient to stop the pandemic. Multiple mathematical models have demonstrated that the implementation of face masks did mitigate the spread of the virus [3, 4] . Since 2021, the scenario has shifted with the rollout of vaccinations campaigns mixed with the emergence of new SARS-CoV-2 variants with different transmission rates and capable of evasion from the protection provided by the vaccine [5, 6] .

SARS-CoV-2 is an RNA virus capable of mutagenesis, and new variants have emerged in the ongoing COVID-19 pandemic. The mutated variants are characterized by different sets of mutations and may show varying levels of infectiousness, lethality, and response to the vaccine. The most threatening ones are identified as variants of concern (VOCs) [7] . For example, the SARS-CoV-2 alpha variant, designated B.1.1.7 under the Pango lineage, is among one of the first VOCs. This variant has an N501Y mutation, for which the affected amino acid residue determines how well the virus will interact with the hosts cellular receptor angiotensin-converting enzyme (ACE2) [8] . This mutation resulted in the alpha variant having a 75% higher transmission rate than the original strain [9] . Another important variant, delta or B.1.617.2, was identified in December 2020 and by April 2021 became the most common variant [10] . This variant is characterized by mutations in the spike protein that have the ability to affect the immune response of the host and enhance transmission. Creating a variant that is 60% more transmissible than the alpha variant and resistant to the vaccine [11] .

Mass vaccination started in the US in mid-December with the deployment of BNT162b2 (Pfizer/BioNTech), followed by mRNA-1273 (Moderna) and

Ad26.COV2.S (Janssen, J&J, the only vaccine of one dose). By the beginning of May 2021, 34.6 of the US population had been fully vaccinated by either one of these three vaccines [12, 13] . While vaccines applied in the US are highly effective in controlling the spread of the Wild-type SARS-CoV-2 strains, they show different effectiveness against new strains like alpha and delta variant [14] . This difference implies that the trajectory of the COVID-19 pandemic will depend on several vaccine related parameters. Multiple mathematical models have been derived to evaluate the behavior of COVID-19, but not many evaluate the dynamics of the spread of a two-strain pandemic. For example Gonzalez-Parra et al, 2021 [15] derived a compartmental model based on differential equations to evaluate how a new variant can affect the behavior of the pandemic, generating more infections, hospitalizations and deaths [15] . Another important mathematical model using control theory considered multiple strain and waning immunity from natural infection [16] . Both mathematical models describe the interaction between two or more variants, but they do not evaluate the importance of vaccine to stop the spread. Model formulation by Tchoumi et al, 2021 incorporated vaccination in two strain dynamics; they showed that a variant would become dominant if it had a higher reproduction number with respect the other strain. This study only considered vaccine effectiveness for the dynamics of the spread, and the compartment for exposed population was not considered, a latent stage that is present in COVID-19.

We developed a mathematical informed approach where we depict the dynamics of two strains under one vaccination regime, applied to the US COVID-19 pandemic. We quantified the impact of SARS-CoV-2 variants and their response to the vaccination strategy on developing new infections and deaths. Our approach directly addresses the behavior of a vaccine and how it manages to reduce the spread of a virus. It also includes parameters of an imperfect vaccine [17] and three levels of transmission: low, where non-pharmaceutical intervention strategies (NPI) are heavily implemented; baseline, NPI strategies are relaxed; and high transmission where no NPI are deployed. In terms of the vaccination rate, we acknowledge three rates: 50% less than the baseline rate, baseline rate and 200% of the baseline rate. The rest of the paper is structured as follows. We formulated the mathematical model, computed the basic reproduction number, and conducted the local sensitivity analysis. We also derived the minimum percentage of vaccination and the stability of the disease-free equilibrium. In section 3 we calibrated our mathematical model using daily cumulative of infected and death individuals and the global sensitivity analysis of the set of differential equations. In section 4 we explore the simulations of the cases in the US between variants.

Lastly, we provided discussion and conclusion remarks in section 5.

We develop and apply a compartmental differential equation to understand the vaccinated with Pfizer, : exposed to strain one, : infected with strain one, :

infected asymptomatic with strain one, : exposed to strain two, : infected with strain two, : infected asymptomatic with strain two, R: Recuperated from strain one or two and D: death by either strain one or two.

We do not consider any natural recruitments (births) at any time . Susceptible population decreases when they interact with a symptomatic original variant infection at a rate 1 and an asymptomatic original variant infection at a rate 2 . Also, they become exposed with a symptomatic alpha variant at a rate 3 and asymptomatic at a rate 4 . The susceptible population may increase at a rate associated with the waning rate of a vaccine, describing that protection descends over time and vaccinated individuals become fully susceptible to infection at a rate . Finally, the susceptible population will be vaccinated at a rate ≥ 0, multiplied by the all or nothing protection of a vaccine (1 − ) which means individuals who received the vaccine, but the vaccine fails to protect a fraction of individuals. The rate of change of the susceptible population is expressed in the following equation:

(1)

Population exposed to strain 1, ( ): Because we are simulating an infection caused by a virus, we need to include the exposed population. This subpopulation are individuals that are infected but not infectious. It increases at a rate of infection 1 and 2 for symptomatic and asymptomatic infection from strain, this increase is due to unvaccinated individuals. In addition, it increases with individuals who are already vaccinated but develop a symptomatic infection at a rate (1 − ) 1 and an asymptomatic infection at a rate (1 − ) 2 . This behavior is associated with the leakiness or vaccine efficiency, that describes when the vaccine reduces but does not eliminate the risk for infection. This population decreases at a rate , which denotes the average length of the latent period. Hence,

Population infected by strain 1, ( ): Infected individuals that develop symptoms for the original variant are generated at a proportion ∈ (0,1) from the exposed subpopulation. They recover at a rate 1 and die from the disease at a rate 1 . Consequently, rate 4 for asymptomatic individuals, both from strain 2 and unvaccinated individuals. Moreover, vaccinated individuals who interact with symptomatic or asymptomatic are incorporated at a rate (1 − ), which is the vaccine efficiency associated with that strain. Also, individuals that are vaccinated and protected from strain 1 can get re-infected and develop symptoms or not at a rate 3 and 4 respectively from strain 2. This subpopulation deceases at a rate , the length were individuals pass from infected to infected and infectious. Hence,

Population infected with strain 2, ( ): All individuals that are infected and develop symptoms at a proportion ∈ (0,1) who will recover at a rate 2 and die at a rate 2 . Consequently,

Asymptomatic population infected with strain 2, ( ): individuals that are infected but do not develop symptoms at a proportion (1 − ) from the exposed class. They recover at a rate 2 . So,

Recovered population, ( ): All individuals infected with symptoms or not will recover at a rate 1 from the original variant and a rate 2 from the alpha variant.

We acknowledge in this population the loss of protection from natural immunity at a rate . As well recovered individuals vaccinated or not can get re-infected with another SARS-CoV-2 variant at a rate 3 and 4 for symptomatic or asymptomatic infections respectively. Consequently, 

Henceforth, the system of differential equations that will simulate the dynamics of the original strain and the alpha variant with vaccination is:

We can derive that ( ) at a time is given by, ( ) = ( ) + 1 ( ) + 1 ( ) + 1 ( ) + 2 ( ) + 2 ( ) + 2 ( ) + ( ) + ( ) + ( )

In our mathematical model, there exists a disease-free equilibrium which happens when the vaccination rate = 0. So 1 = 1 = 1 = 2 = 2 = 2 = 0, and the disease-free equilibrium is: 0 = ( * , 0,0,0, * , 0,0,0,0)

Where * ≥ 0 and * > 0.

This equilibrium represents where the vaccination logistic program has ended, with a certain number of individuals that are vaccinated, and a population that may be susceptible to get infected. We will compute the control reproduction number in this disease-free equilibrium. By applying the next generation method to find , we must solve the following equation: = ( −1 ) [12] . Where F are the derivatives of the new infections, V is the transition matrix (flow between compartments) and is the spectral radius. The entire derivation of is as follows.

The matrix of new infections ℱ is given by

While the transition matrix is given by

Using the following transformations ′ = − , ′ = −(1 − ) , = 1 + 1 , Since is −1 upper triangular, we have that −1 − 6 is also triangular, whence its determinate is the product of the main diagonal, that is, the characteristic polynomial is given by We apply the same idea to the control reproduction number for the second strain. 

The vaccine impact is given by:

Hence,

We follow the same calculation for the control reproduction number for strain 2.

Consequently,

Based on the derivation of the control reproduction numbers, we can compute the minimal fraction of the population of the US that need to be vaccinated so that they can achieve herd immunity or asymptomatic eradication of COVID-19 by placing Setting ( ) = 1 and solving , we obtain a herd immunity threshold, or the minimum of percentage denoted as .

We apply the same derivation for the control reproduction number for the second strain, the herd immunity threshold for the second strain is

The stability of our disease-free equilibrium can be explained in the following theorem [11] : the disease-free equilibrium = ( , 0,0,0,0,0,0,0,0,0,0) of our system of differential equations is locally asymptomatically stable if < 1 and unstable if > 1. We calculate the Jacobian matrix of our system of differential equations at the disease-free equilibrium, which is given by

we have the associated characteristic polynomial to the Jacobian matrix in infection-free equilibrium equaled to 0 is

In this way the Jacobian matrix has a null eigenvalue 1 = 0, two negative eigenvalues 2 = − − y 3 = − . Three other eigenvalues are determined by the solutions of

While the remaining three are the solutions of

We will perform a sensitivity analysis for the control reproduction number for strain 1 (12) and strain 2 (13) to visualize the importance of each parameter in disease transmission. The values obtained from the sensitivity analysis permits us to see how ( ) changes when a parameter varies. To obtain these values we use the following definition (6):

If is differentiable with respect to a given parameter , the normalized forward sensitivity index of is defined by Γ = * .

First we will calculate the local sensitivity analysis for the control reproduction number for strain 1 ( ( )) with respect to the following parameters 1 , 2 , , , , 1 and 1 . Thus, (25) . (26) .

] (30) .

.

Equations 24-33 will be substituted with the value of each parameter in table S1 to evaluate if they decrease or increase the control reproduction number of strain 1.

The derivation of the local sensitivity analysis for the control reproduction number of strain 2 is included in the supplementary material.

To estimate the parameters of the two variant comparisons, it was divided into two parts: First the parameters for the original variant vs alpha variant, then the alpha variant vs delta variant. To describe the evolution of the two-strain COVID-19 pandemic in the US, taking into account the vaccination rate and the level of implemented NPI, we assumed that the infection, recovery, and death rate are time-dependent functions like described in [18] . For estimating parameters for the original variant, we considered the data of COVID-19 infections, recovery, and death from the period of November 11th, 2020 to December 12th, 2020, the date before the vaccination period began in the United States [13] . Parameter estimation for the original variant was pursued by applying a vaccination rate equal to zero and the subpopulation associated with the alpha variant equal to cero as well. For the alpha variant, the estimation of the parameters was the same, only the subpopulation for the original variant was equal to zero. We used the global proportion of alpha infections from the CDC genomic surveillance from January 25th to May 31st. For the delta variant, we used the same approach for the alpha variant, but the time period was from June 1st to July 31st.

For this approach, there were only two fixed parameters the average length of the latent period and the proportion of symptomatic individuals. For the alpha variant, the estimation of the parameters was the same, only the subpopulation for the original variant was equal to zero. The system of differential equations was solved using Matlab R2016b and ODE45 solver. The parameters were fitted by applying two methods, first the one mentioned in [18, 19] . The code and implementation can be downloaded at https://github.com/UgoAvila/Two-Strain-Covid-19-Mathematical-Model-in-the-US.

To perform local sensitivity analysis, we performed a one-at-a-time parameter evaluation. This approach allows us to evaluate the impact of the partial derivative of a parameter with respect to changing the input of said parameter in the control reproduction number. The sensitivity analysis of the control reproduction number was carried out using the following definition [20] :

If is differentiable with respect to a given parameter, the normalized forward sensitivity index is defined by

We obtained the partial derivatives of each parameter, with respect to the control reproduction number, the equations for each parameter are represented in section 2.2 of the theoretical analysis of the derivation of the mathematical model. Once

we obtained the values of the parameters (Table S1 ), we were interested to perturb them to determine how their changes affect the reproduction number, we solved the equations using Mathematica. A positive sign of the parameter correlates with an increase of the control reproduction, meanwhile, a negative sign is associated with a decrease of the control reproduction number. Local sensitivity analysis was carried out to obtain which parameters are the most important to decrease the control reproduction number, in turn, find which are the parameters that we must avoid so that the reproduction control number does not rise.

Unlike local sensitivity analysis, global analysis allows us to quantify the impact of the inputs (parameters) and their interaction with the outputs (for example dynamics of fully vaccinated individuals). To identify which parameters are important for the behavior of our compartmental differential equations, we applied and adaptive to our model the technique in [21] . We sampled our 17 parameters and evaluated which were important in determining the behavior of our model. All 

We simulated immunity acquired by two doses of the BNT162b2 vaccine (the first FDA-approved COVID-19 vaccine) against the original virus, alpha, and delta variant. We used this vaccine because it is the vaccine most widely applied in the Us (~60% of the US vaccinated individuals have received BNT162b2 [12] ) and the availability of real-world effectiveness data [22, 23] in the period during alpha was the dominant strain [22] , followed by the period when delta was the dominant strain [23] . [23] . We also included the all-or-nothing protection, which means people who received the vaccine, but the vaccine fails to protect a fraction of individuals. This value is 0.0862 (CI, 0.0689,0.10344). Finally, waning immunity describes that protection descends over time, and vaccinated individuals become fully susceptible to infection at a rate. Parameter was assumed herein by vaccine-induced immunity being worn off after six months and represented a conservative estimate that may apply for a variant with high resistance to vaccine-induced immunity. We also obtained the transmission rates for symptomatic and asymptomatic infections by fitting the parameters using data of daily infections and deaths provided by the repository developed by Johns Hopkins University [1] .

To approximate the real-world situation, we further considered vaccination rate as a function that varies in time instead of a constant. The daily anti-SARS-CoV-2 vaccines applied in the US from December 12th to July 20th were plotted (Fig. 1A) and used to derive a function that represented the projected vaccination rate.

Based on this projection (black line), if the US maintains the baseline vaccination rate from May 1st to December 2021, over 65% of the population of the US will be vaccinated (Fig. 1B) . We also simulated the percentage of the population that will be vaccinated given a 200% or 50% project vaccination rate from May 1st. The real-world vaccination rate may vary due to a wide range of factors, and thus we simulated all three situations in subsequent models. 

In this section we evaluated how different vaccine rate affect the spread of the virus. In the scenario of low transmission in the community the different vaccination rates stabilized the infection by the original strain and the alpha variant. The cases of infected individuals regardless of the strain was stable between June and July 2021 due to the actions of the vaccine (Fig 3A) . If a new variant is not entered or surges in this period by August 2021, the cases of SARS-CoV-2 will continue to descend (Fig 3A) . The red dotted line is the scenario where no vaccines are being administered, despite the use of NPI, the US would have a fourth wave. The asymptomatic infections behave in the same manner, increasing the daily doses up to 200% it does not deaccelerate the new infections of SARS-CoV-2 ( Fig 3B) . The dynamics of recuperated individuals is not affected by the vaccination rate ( Fig   S1A) and death rate is affected and controlled significantly by the vaccines applied ( Fig SB) . The latter scenario was modeled where NPI strategies are still being used, a scenario that in the US does not hold. The normal or baseline transmission does affect the dynamics of the spread. Infected SARS-CoV-2 cases nearly doubled with respect to low transmission rate. June and July 2021 will be the period with more SARS-CoV-2 cases, roughly 20 million accumulated cases and since then the cases will descend (Fig 3C) . Most of the cases between this period will be from the alpha variant, the original variant was contained by the vaccine.

Asymptomatic infection is detained by vaccination rate, but the difference between the rate is little but significant (Fig 3D) . Recuperated individuals are not altered by vaccination rates (Fig S1C) . By early July 2021, there will be around more than 600 00 deaths associated with COVID-19, if the tendency maintains by the end of July 2021 there will be 620 000 deaths. If we compare baseline transmission deaths with low transmission nearly 50 000 deaths could have been avoided if NPI had been maintained. In the scenario of high transmission of the alpha variant, the pharmaceutical intervention will not be enough to stop the spread, other strategies need to be applied (Fig 3E and F) . Recuperated individuals do not change their rate despite vaccination rates, meanwhile death rate can be altered due to the amount vaccine applied (Fig S1E and F) . We begin with low efficiency and low vaccination rate (LVR) from both variants.

From February to May 2021, the cases of infection of SARS-CoV-2 dropped drastically, this behavior is because of the action of a vaccine in lowering the infections produced by the original variant (Fig S2A) . But in June 2021, the tendency shifted from a 4-month decay to a slightly growth of infections mainly because of an increase of the alpha variant (Fig 4A) . Cases from the alpha variant will still increase in the following months of no new variant is introduced, this increase is associated with a low daily doses application presented since June 2021 (Fig 1) . We can observe as well that regardless of the vaccine having high efficiency mixed with a low vaccination rate the cases of COVID-19 from the alpha variant will increase rapidly. The increase of cases may be due to a high population of people not vaccinated and not from breakthrough cases of individuals vaccinated (Fig 4D and G) . Once transmission is little high, we can see a difference on the imperfection parameters of a vaccine, the highest number of infections will be roughly between September and October 2021 (Fig 4 D and G) .

There is no variation in recuperated individuals and death rate due to different efficiencies ( Fig S3 A and B) . For the normal vaccination rate (NVR), the valley for symptomatic and asymptomatic was reached between April and May 2021, since then a continuous but stabilized increase is happening (Fig 4B and E) . This change is due to the presence of the alpha variant (Fig 4B) , the imperfection of the vaccine associated with this variant and the relaxation of NPI strategies. Despite relaxation of NPI strategies, the vaccine is helping in lowering the number of infected with the alpha variant. Death toll and recuperated individuals roughly behave the same as low transmission (Fig S3 C and D) . Finally, if there was a high vaccination rate (HVR), the pace of lowering will maintain between April and May 2021. In the summer of 2021, there will be a high community transmission specifically of the alpha variant (Fig 4C) , even the most perfect vaccine is not going to help stop the spread of the virus and alpha as we know will become the dominant if no new variants surges (Fig 4F and I) . Death toll and recuperated individuals roughly behave the same as in the other transmission rates analyzed in this subsection.

This similarity can be associated that the alpha variant does not has a high death rate mixed with the protection provided by the vaccine (Fig S3E and F) . 

To evaluate the behavior of the control reproduction number for the alpha variant and the original we substituted equation 12 and 13 in terms of two important populations: vaccinated (acquired immunity) and recuperated (natural immunity) to reduce the and achieve herd immunity. Consequently, a scenario of the disease-free equilibrium mentioned above is = ( * , 0,0,0, * , * ) and the total population is * = * + * + * . We can rearrange equation 12 in the following manner:

Because we want to define a proportion of susceptible, vaccinated and recovered individuals, we can divide equation20 by the total population. So, * * + * * + * * = 1, * * = * * = .

It follows that, * * = 1 − − . 

In a scenario of low transmission for the alpha variant, to reduce the value of = 1 we need 60% of fully vaccinated individuals in combination with natural immunity despite the efficiency of the vaccine. In the case of baseline transmission to reduce the value of = 2 (which is still an increasing disease) we need less than 30% of acquired immunity, we can observe that natural immunity impact in diminishing the is absent in this transmission. To reduce the value of = 1, we need more than 70% of individuals fully vaccinated (Fig S5) . In an event of high transmission, we noticeably need more vaccinated individuals of roughly 80% to reduce the growth to a more stabilized pace of SARS-CoV-2. By the final days of July, the US has only 50% of individuals fully vaccinated, which may not be sufficient to reach herd immunity regardless of the variant. (Fig 4 and Fig S5) . If we increase the vaccination rate, we can diminish the due to the protection of the vaccine, but if the protection wanes, the augments in the same index ( Fig   6B) . 

Mathematical models are vulnerable to large variations regarding social interactions that can shape the behavior of our model forecasts. To model this impact, we used a global sensitivity approach with the partial rank correlation coefficient (PRCC). We are only interested in those parameters whose p-value is less than or equal to 0.05, basically the parameters that do not have a bar height ( Fig 7B, D, F and H and the B panel for Fig S6 through S10) . Exposed individuals to the original variant are affected by some parameters (Fig S6A and B) . The parameter associated with time between the onset of symptoms (w) is involved in decreasing this population, this means that the latent stage is over, and the infectious period is starting to commence. The force of infection of symptomatic or asymptomatic infections ( 1 , 2 ) are implicated in increasing this population, because more individuals are entering the latent stage once they were infected by positive cases regardless of whether or not they have symptoms. Vaccine effectiveness ( , ) to this variant is associated in decreasing this population (Fig S6A) , because if the acquired immunity is higher the probability of getting infected once an individual gets in contact with a positive case is lower. Enhancing the vaccination rate is involved in decreasing this population because the probability of getting in contact with a positive case is lower since most individuals are vaccinated and indirectly protecting individuals that are not (Fig S6A) . Waning immunity is associated with increasing the population of exposed individuals because they become susceptible to infection again (Fig S6) . increasing the population of infected individuals, because protection is wearing off (Fig 7A and B) . Asymptomatic individuals to the wild type variant are affected by the same parameters, only at a different rate (Fig S7) . For Vaccinated individuals only two parameters are statistically significant (Fig 7D) in shaping the behavior.

Increasing the vaccination rate is positively correlation in increasing this population, meanwhile waning immunity is strongly correlated in decreasing this population (Fig 7C and D) . Exposed individuals to the alpha variant behave in the same manner as exposed to the original variant ( Fig S8) . Infection by the alpha variant is enhanced by the force of infection for symptomatic and asymptomatic associated with this variant (Fig 7E and F) . The recuperation rate associated with this variant 

In this section we evaluated the behavior between the alpha and the delta variant. August 2021, there will be between 500 000 and 1 million active symptomatic cases. Despite the vaccination the tendency of increment of cases will maintained passing October 2021 for symptomatic or asymptomatic cases (Fig 8A and B) . In a normal transmission rate, the vaccination rates in slowing infected new cases still matter, by August 2021 there may be roughly two million infected individuals mixed with 5 million cases of asymptomatic cases (Fig 8C and D) . For a scenario with high transmission, accelerating the vaccination rate to 200% (black line) will help diminish the cases but it would not be enough, other strategies like NPI need to be included. The recuperation increases with respect to vaccination rates and death rates pace can be diminished by the action of the vaccine (Fig S11) . Overall, the efficiencies of the vaccine in preventing infection by the delta variant affects the number of infected individuals (Fig S12) , but relying on the vaccine efficiency is not sufficient to halt the spread of the delta variant and other measures would be needed (Fig S13) . 

We computed the reproduction number of the delta variant. For the scenario of a low transmission (non-pharmaceutical strategies are still being used), in conjunction with low efficiency, vaccinating the entire population is not enough to decrease the value lower than = 2 ( Figure 9A ). With baseline vaccine effectiveness as in low transmission is not enough to decrease the value of .

High efficiency of the vaccine with 80% of vaccinated individuals the = 2, and 90% reduces the value of the control reproduction number to 1.5 (Fig 9G) . For Baseline transmission, low and baseline efficiency will not be enough to reduce the ( Fig 9B and E) . Only high efficiency with more than 90% of the individuals vaccinated will decrease the value of less than 2 (Fig 9H) . In a scenario of high transmission, only high efficiency will try to descend the value of the (Fig 9C, F and I). But other strategies need to be applied to reduce the control reproduction and descend the spread of the delta variant in the US. parameter. We only describe the parameters whose p value is equal to or less than 0.05, in this case those whose height of the histogram is not observed in the figure.

Exposed individuals to the delta variant are affected by which is statistically significant ( Figure S14B ) the parameter associated with developing symptoms; this parameter is associated with increasing individuals of the exposed subpopulation.

The force of infection of symptomatic ( 3 ) or asymptomatic ( 4 ) of the delta variant is involved in increasing this subpopulation. The recuperation rate ( 2 ) is implicated in diminishing the population of exposed individuals. Vaccine effectiveness ( ) towards the delta variant is correlated in decreasing this subpopulation, as well the rate of vaccination ( ) is involved in decreasing this subpopulation. The waning immunity or loss of protection provided by the vaccine is correlated in increasing this population ( ). The loss of protection provided by the antibodies after recovering from the delta variant has no relation in modifying the dynamics of the exposed population because it is not statistically significant ( Fig S14A and B) . For the vaccinated individuals their behavior is different with respect to the variant. The force of infection ( 1 , 2 ) of the alpha variant has no relation with the dynamics of this subpopulation because it is not statistically significant (Fig 11A and B) . Meanwhile the force of infection ( 3 , 4 ) of the delta variant are involved in decreasing this subpopulation, which means despite being vaccinated your most likely to get infected by the delta variant than the alpha. The vaccine effectiveness regardless of the variant are involved in increasing this subpopulation, but the effectiveness ( ) from the delta virus it increases at a higher pace than the effectiveness from alpha ( ) (Fig 11A) . The vaccination rate ( ) is positively correlated in increasing this subpopulation and the waning rate in decreasing this subpopulation, note that this parameter has a strong negative correlation with this subpopulation, this imperfect parameter needs to be monitored. For the infected symptomatic individuals of the delta variant, the force of infection ( 3 , 4 ) are strongly correlated in increasing this subpopulation ( Fig   11C) , meanwhile the recovery rate ( 2 ) is associated in decreasing this subpopulation (Fig 11C and D) . The vaccine effectiveness parameter ( ) is correlated in decreasing the subpopulation of infected individuals, this decrease has a strong correlation. The vaccination rate and waning immunity behave in the same manner as in the other subpopulation evaluated in this section.

Asymptomatic individual of the delta variant behaves in the same manner as symptomatic individuals (Fig S15A and B ). Diseased individuals increase by the action of the force of infection of the delta variant, alpha variants force of infection have no relation in affecting the dynamics of this subpopulation (Fig 11E and F) .

Vaccine effectiveness of the delta variant can decrease the population of diseased individuals at a strong correlation. The vaccination rate decreased this subpopulation, instead waning immunity increases this subpopulation, because the protection provided by the vaccine is wearing off (Fig 11E and F) . 

In a population, the proportion of individuals immune against the virus sufficient to prevent the spread is considered "herd immunity" and may be achieved by a combination of natural immunity or acquired immunity (vaccination). For COVID-19, the natural immunity acquired by infection may result in a higher mortality rate (ex. Sweden relative to their neighbor countries that implemented NPI´s throughout 2020) [25] , although vaccination alone may not be sufficent [26] . The theoretical derivation was obtained in section 2.2 and we used the parameters from table S1

for each variant in question. We depicted in the following figures how vaccine coverage or proportion mixed with vaccine efficiency affects the behavior of the control reproduction number of each strain. The results for the comparison between original and Alpha variants during the period between March and July 2021 are in figure 12 for Alpha and in figure S16 for original. For the original variant mixed with NPI's the control reproduction number ranges from 1.3 to 0.7 (Fig S16) ,

where the decreases as vaccine coverages and efficiency increase. In the scenario of low transmission, where we explore the impact of NPI´s and 50% of the population vaccinated to decrease the value of the control reproduction number to 1.2. There is no difference in reducing the between a higher efficiency or higher percentage in low transmission. In the case of baseline transmission with 80% of efficiency and 60% for the population vaccinated the value of will be 1.5 ( Fig   S16B) . For high transmission, we will need a higher vaccine coverage and efficiency to reduce to a value of 1.8 (Fig S16C) . For the Alpha variant in 80% vaccine efficiency and 60% individuals vaccinated, the will only decrease to a value of 1.6. The same pattern is observed in baseline and high transmission, we need more vaccine coverage to reduce the value of to 1.9 and 2.5 respectively ( Fig S17) . For the delta variant, the only scenario where the value of may be less than 2 is when strict NPIs are still being used mixed with vaccination. With 80% of vaccine efficiency and a coverage of 60%, the pandemic will not decrease and reach a plateau of infected cases. For baseline and high transmission, the value will never decrease from 2. For this variant, non-pharmaceutical strategies still need to apply for the reduction of the control reproduction number (Fig 12) . 

Our mathematical model allowed us to evaluate which are the most important characteristics of the variants to become the dominant strain in a partially vaccinated population before the arrival of omicron in the US in early December 2021. Many of the variants of concern/interest have higher transmissibility than the origin variant that emerged from Wuhan, but as we can see this attribute is not sufficient to give rise to a dominant strain [27] . The alpha variant took a long duration to become the dominant strain in early 2021 despite being more transmissible [9] . This was because the immune escape of the alpha variant was not higher than the original variant. For the mRNA vaccines (BNT162b2 and mRNA-1273.211), which were being applied when the alpha variant arrived in the US, their neutralizing activity decreased only 3.3 fold compared with the original variant, and there was no evidence of immune escape [28, 29] . Even the Beta and Gamma variants were better at evading the protection acquired by mRNA vaccines [30, 31] but their transmissibility was not as higher compared with the alpha variant [32] . The Johnson & Johnson single-dose vaccine also had a neutralizing effect against alpha.

The delta variant was first detected in December 2020 and quickly became the common variant across many countries in 2021 [33] . This speed may be attributed to two main reasons: delta had a higher transmission rate than alpha even in vaccinated individuals. In addition, several individuals in the US population had received the full regimen of vaccination for many months, a period where the immunity waned with respect to the delta variant [34, 35] . Higher transmission mixed with a decrease in the neutralization effect, demonstrating the immune escape capacity of the delta of the protection provided by vaccination [36] gave rise to delta becoming the dominant strain causing another pandemic wave in the US; this wave was slightly controlled with the application of the booster dose, which generated greater protection against infection with delta [6] . At the time of writing, the omicron variant has swiftly taken over as the dominant strain across the US and much of the world, stressing the importance of considering multi-strain dynamics in a pandemic.

Our model has several limitations, some of which are addressed in other new models developed under this pandemic. First, our model does not consider the population heterogeneity, which has shown to tamper the required number of vaccinated individuals to achieve herd immunity [37] . Other models have been used to plan the strategy of vaccination to reduce death or infections [38] . Second, we do not consider one vs two doses and the variation of immunity for individuals with different doses. Saad-Roy et al. [39] developed a mathematical approach wherein the short term having more individuals with one dose will reduce infections, but in a long term, the virus can mutate and develop characteristics to avoid elimination by the immune response [40] . We obtained the immunity parameters for the Pfizer vaccine that is the most widely used in the US, but our model can be further extended using data for other vaccines. Third, we did not consider seasonality. And lastly, we only considered two strains, although the pandemic is characterized by multiple strains each with its own transmission dynamics and associated immunity parameters. While the dominant strain has shifted in this pandemic, the model developed herein, especially considering the variant's different transmission rates and responses to vaccines, may be adapted and modified to reflect the multi-strain nature of future pandemics.

Ugo Avila Ponce de León also received a fellowship (CVU: 774988) from Consejo 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The original contributions presented in the study are included in the article/Supplementary Material. All code used for analysis is available at https://github.com/UgoAvila/Two-Strain-Covid-19-Mathematical-Model-in-the-US.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

An interactive web-based dashboard to track COVID-19 in real time

Non-pharmaceutical interventions during the COVID-19 pandemic: A review

Optimal Control of the COVID-19 Pandemic with Nonpharmaceutical Interventions

Could masks curtail the post-lockdown resurgence of COVID-19 in the US?

Genetic Variants of SARS-CoV-2-What Do They Mean?

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA -first update

Delta coronavirus variant: scientists brace for impact

A global database of COVID-19 vaccinations

Will vaccine-derived protective immunity curtail COVID-19 variants in the US?

Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach

Modelling and optimal control of multi strain epidemics, with application to COVID-19

Vaccine impact in homogeneous and age-structured models

An SEIARD epidemic model for COVID-19 in Mexico: Mathematical analysis and state-level forecast

Chinese and Italian COVID-19 outbreaks can be correctly described by a modified SIRD model

Sensitivity analysis in a dengue epidemiological model

A methodology for performing global uncertainty and sensitivity analysis in systems biology

Effectiveness of the BNT162b2 Covid-19

Vaccine against the B.1.1.7 and B.1.351 Variants

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Online Version)

The concept of herd immunity and the design of community-based immunization programmes

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Covid-19: What new variants are emerging and how are they being investigated?

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2

Modelinformed COVID-19 vaccine prioritization strategies by age and serostatus

Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

Ugo Avila Ponce de León is a doctoral student from Programa de Doctorado en Ciencias Biológicas of the Universidad Nacional Autónoma de México (UNAM).This paper was developed in the period of his Ph.D. studies. Ugo Avila Ponce de León also received a fellowship (CVU: 774988) from Consejo Nacional de Ciencia y Tec-nología (CONACYT).